



## Company Overview

Aethlon Medical develops immunotherapeutic technologies to combat infectious disease and cancer. To augment the body's natural immune defenses, the Aethlon Hemopurifier® reduces the presence of circulating viruses in infected individuals. The technology provides a first-line candidate defense against viruses that are not addressed with proven drug therapies, including natural occurring pandemic threats and agents of bioterrorism. The Hemopurifier® can also be deployed as a strategy to improve the benefit of approved antiviral drug regimens. At present, the Hemopurifier® is being advanced in the United States under an FDA approved clinical study. Aethlon Medical is also investigating the potential use of the Hemopurifier® to reduce the presence of tumor-derived exosomes, which contribute to immune-suppression and the spread of metastasis in cancer patients. Aethlon Medical is also the majority owner of Exosome Sciences, Inc. (ESI), which is focused on the discovery of exosomal biomarkers to diagnose and monitor cancer and neurological disorders, including Alzheimer's disease (AD) and Chronic Traumatic Encephalopathy (CTE). ESI's TauSome™ biomarker is being clinically evaluated as the basis for a blood-based test to identify CTE in living individuals.

## Aethlon Medical to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

Sep 9 2020, 8:01 AM EDT

## Aethlon Medical to Present at the LD Micro 500 Virtual Conference

Aug 27 2020, 8:01 AM EDT

## Aethlon Medical Announces First Quarter Financial Results and Provides Corporate Update

Aug 11 2020, 4:15 PM EDT

## Stock Overview

Symbol	AEMD
Exchange	Nasdaq
Market Cap	16.17m
Last Price	\$1.34
52-Week	\$0.764 - \$6.89

09/25/2020 04:00 PM EDT

## Investor Relations

Aethlon Medical, Inc.  
Jim Frakes  
CFO  
9635 Granite Ridge Dr.  
Suite 100  
San Diego, CA 92123  
[jfrakes@aethlonmedical.com](mailto:jfrakes@aethlonmedical.com)

## Management Team

### Timothy C. Rodell, M.D., FCCP

Chief Executive Officer and Director

### James B. Frakes

Chief Financial Officer and Senior Vice President – Finance

### Thomas L. Taccini

Vice President, Manufacturing and Product Development

### Annette Marleau, PhD

Senior Director of Research

### Lisa M. Boswell

Director, Quality Systems and Regulatory Affairs

### Michael Jacobs

Senior Scientist

## Aethlon Medical, Inc.

9635 Granite Ridge Drive  
Suite 100  
San Diego, CA 92123

## Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.